Illumina Sues Oxford Nanopore for Patent Infringement
News Feb 24, 2016
The lawsuits were filed concurrently with the U.S. International Trade Commission and in the U.S. District Court for the Southern District of California. Illumina is seeking all available remedies.
The lawsuits are based on U.S. Patent Nos. 8,673,550 and 9,170,230, which are entitled “MSP NANOPORES AND RELATED METHODS.” Illumina has exclusively licensed the patents in the field of nucleic acid sequencing from the UAB Research Foundation and the University of Washington. The lawsuits focus on ONT’s MinION and PromethION devices.
Illumina has made substantial investments to obtain licenses and develop the nanopore sequencing technology invented by researchers at the University of Alabama at Birmingham and University of Washington. Illumina filed the lawsuits to protect its investment and patent rights in this technology.
Computer scientists at Carnegie Mellon University say neural networks and supervised machine learning techniques can efficiently characterize cells that have been studied using single cell RNA-sequencing (scRNA-seq). This finding could help researchers identify new cell subtypes and differentiate between healthy and diseased cells.